Market Overview - On September 1, the medical services sector rose by 3.84%, with Yingkang Life leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Services - Yingkang Life (300143) closed at 12.00, up 12.78% with a trading volume of 544,600 shares and a transaction value of 639 million [1] - Zihua Medicine (600721) closed at 9.85, up 10.06% with a trading volume of 562,700 shares [1] - Innovation Medical (002173) closed at 25.19, up 10.00% with a trading volume of 1,271,700 shares and a transaction value of 3.071 billion [1] - Other notable gainers include Puwis (301257), Baicheng Medicine (301096), and WuXi AppTec (603259) with respective increases of 8.59%, 8.46%, and 8.02% [1] Market Capital Flow - The medical services sector saw a net inflow of 1.699 billion in main funds, while retail funds experienced a net outflow of 1.134 billion [2] - The main funds showed a positive trend in several stocks, particularly WuXi AppTec with a net inflow of 1.087 billion [3] Individual Stock Performance - WuXi AppTec (603259) had a main fund net inflow of 1.087 billion, while retail funds saw a net outflow of 660 million [3] - Innovation Medical (002173) experienced a main fund net inflow of 405 million, with retail funds showing a net outflow of 240 million [3] - Sanbo Brain Science (301293) had a main fund net inflow of 152 million, while retail funds saw a net outflow of 107 million [3]

Group 1 - The core viewpoint highlights a significant upward trend in the medical sector, with major players like WuXi AppTec and United Imaging Healthcare experiencing substantial gains of over 7% and 6% respectively, alongside a notable increase in trading volume for the largest medical ETF in A-shares [1][3] - The medical ETF (512170) has shown a year-to-date increase of over 20%, indicating a strong recovery in the medical sector, yet it remains approximately 60% below its historical peak from 2021, suggesting considerable potential for further gains [3][4] - The current price-to-earnings (PE) ratio for the medical ETF's underlying index is around 36 times, which is still lower than 60% of the time over the past decade, indicating a favorable cost-performance ratio for investors [3][4] Group 2 - The ongoing bull market trend in A-shares presents an opportunity for low-valuation sectors like healthcare to experience a rebound, making it a focal point for investors [4][6] - The medical sector, particularly the medical ETF (512170) and its linked fund (012323), is emphasized as a key investment tool, focusing on medical devices (52%) and medical services (40%), which are closely related to AI healthcare [6][7] - The pharmaceutical sector is also highlighted, with a recommendation to consider the only pharmaceutical ETF (562050) and its linked fund (024986), which focuses on the top 50 pharmaceutical companies in A-shares, emphasizing innovative drugs (60%) while excluding medical and CXO sectors [7]

Core Insights - The report highlights the rapid development of the communication industry supported by multiple policies, particularly in satellite direct connection applications, with related stocks including Zhenlei Technology (688270) and China Satellite Communications (601698) [8] - The successful clinical trial of brain-machine interface technology for precise tumor boundary localization marks a global first, with associated stocks being Zhongke Information (300678) and Sanbo Brain Science (301293) [8] - The release of the AI computing platform version 5.0 and the official launch of Kunlun Core Node are significant advancements, with related stocks also including Zhongke Information (300678) and Sanbo Brain Science (301293) [8] Industry Latest Developments - The report discusses the collaboration between the Chinese Academy of Sciences and Harbin Medical University in successfully completing a clinical trial for brain tumor localization using implanted microelectrode arrays [6] - The Ministry of Commerce plans to enhance the implementation of the departure tax refund policy to boost inbound consumption [6] Company Focus - Meihua Medical (301363) has taken on all production processes for artificial cochlear implant products except for PCBA and chip manufacturing [10] - Jinsanjiang (301059) intends to invest up to 600 million yuan in establishing a production base in Malaysia for a green, low-carbon high-performance silica project [10] - Longyang Electronics (301389) announced a stock trading anomaly and highlighted its HVLP5 high-frequency copper foil, which is expected to be used in AI servers, communications, and automotive radar applications [10] Market Review and Outlook - On August 29, the total trading volume in the two markets was 27.983 billion yuan, with 1,850 stocks rising and 3,186 falling, indicating a net outflow of 98.59 billion yuan [12] - The three major indices opened flat and experienced slight upward movements, with large-cap stocks outperforming small-cap stocks [12] - Market hotspots included significant inflows into sectors like batteries, liquor, and small metals, while sectors such as semiconductors and communication services saw notable outflows [12] - The report suggests that after breaking through the 3,732-point ten-year high, there may be a need for short-term adjustments around the 3,920-point level, but a significant downturn is unlikely due to the prevailing bull market sentiment [13]

Summary of Sanbo Brain Science Conference Call Company Overview - **Company**: Sanbo Brain Science - **Industry**: Healthcare, specifically focused on brain science and medical technology Key Financial Metrics - **Net Profit**: 72.01 million yuan in H1 2025, up 10.74% YoY [2][3] - **Operating Cash Flow**: 64.76 million yuan, down 21% YoY [2][3] - **Earnings Per Share**: 0.34 yuan, up 6.25% YoY [2][3] - **Total Assets**: 3.719 billion yuan, up 5.34% YoY [3] - **Net Assets**: 2.338 billion yuan, up 1.73% YoY [3] Hospital Utilization and Expansion - **Kunming New Hospital**: Bed utilization rate at 85%, expected to reach 100% within a year [2][5] - **Xi'an Sanbo**: Expected bed utilization to reach 40% by year-end and 60% by early next year [2][5] - **Beijing Sanbo**: Plans to relocate to a new facility with an expected bed utilization of 80% in the first year [2][5] Impact of Healthcare Policies - **Medicare Cost Control**: Stricter policies may delay hospital revenue by 6 to 12 months [2][6][7] - **Non-Medicare Projects**: Hospitals are leveraging pricing advantages in non-Medicare projects to offset revenue losses [2][6][7] Strategic Initiatives - **Brain Science Investments**: Multi-layered approach including basic research, clinical applications, and industrial investments [2][8] - **Partnerships**: Collaborations with institutions like Tsinghua University to drive research and innovation [2][8] - **Brain-Computer Interface (BCI)**: Focus on integrating biomedical and electronic information technologies for medical applications [2][9][10] Future Growth and M&A Plans - **M&A Strategy**: Targeting specialized and general hospitals in the Yangtze River Delta and Pearl River Delta regions [2][4][11] - **New Hospital Developments**: Plans for new facilities in Hunan, with completion expected by August 2025 [2][12] Technological Advancements - **BCI Experiments**: Successful implementation of the first invasive BCI experiment in Fujian, showing promising results [2][14] - **Investment Funds**: Establishment of funds to support AI and BCI innovations, aiming for long-term growth [2][15] Revenue Projections and Challenges - **Revenue from New Facilities**: Expected revenue increases of 5% to 20% post-relocation for various hospitals [2][18] - **Medicare Revenue Share**: Variations in Medicare revenue share across different hospitals, with specialized hospitals generally having lower shares [2][16] Industry Outlook - **Healthcare Service Development**: Focus on improving basic healthcare service quality and leveraging technology for transformation [2][21] - **Technological Empowerment**: Emphasis on external growth and collaboration with tech firms to enhance service offerings [2][22]

Core Viewpoint - Sanbo Brain Science aims to enhance its hospital management capabilities and clinical diagnosis levels while leveraging capital markets for investment in brain science-related medical equipment and pharmaceuticals [1] Investment Strategy - The company plans to establish a limited partnership focusing on brain science, primarily investing in next-generation medical devices, consumables, and drugs for the diagnosis and treatment of brain diseases [1] - Priority will be given to investing in early-stage small and medium enterprises located in the Changping area [1]

Growth - Shudao Equipment reported a net profit of 10.15 million yuan in the first half of the year, a year-on-year increase of 5972.30% [1] - Aerospace Science and Technology achieved a net profit of 88.97 million yuan, up 2161.91% year-on-year [1] - Tianbao Infrastructure's net profit reached 118 million yuan, growing by 2106.58% year-on-year [1] - Northern Rare Earth reported a net profit of 931 million yuan, an increase of 1951.52% year-on-year [1] - Liugang Co., Ltd. posted a net profit of 36.8 million yuan, up 579.54% year-on-year [1] - Cheng Tian Wei Ye's net profit was 10.88 million yuan, increasing by 562.05% year-on-year [1] - Perfect World reported a net profit of 503 million yuan, a year-on-year increase of 384.52% [1] - Shenghong Technology achieved a net profit of 2.143 billion yuan, up 366.89% year-on-year [1] - Zhongke Magnetic Industry's net profit was 20.90 million yuan, increasing by 271.78% year-on-year [1] - Xinjiang Communications Construction reported a net profit of 255 million yuan, up 255.25% year-on-year [1] - Shennong Group achieved a net profit of 388 million yuan, a year-on-year increase of 212.65% [1] - Daikin Heavy Industries reported a net profit of 547 million yuan, up 214.32% year-on-year [1] - Fostar's net profit was 251 million yuan, increasing by 140.45% year-on-year [1] - Guohua Airlines achieved a net profit of 1.24 billion yuan, up 86.15% year-on-year [1] - China Electric Port reported a net profit of 181 million yuan, increasing by 64.98% year-on-year [1] - Ailisi's net profit was 1.051 billion yuan, up 60.22% year-on-year [1] - Zijin Mining reported a net profit of 23.292 billion yuan, a year-on-year increase of 54.41% [1] - Zhongke Chuangda achieved a net profit of 158 million yuan, up 51.84% year-on-year [1] - Sichuan Gold reported a net profit of 209 million yuan, increasing by 48.41% year-on-year [1] - Dongxing Securities achieved a net profit of 819 million yuan, up 42.12% year-on-year [1] - Fosun Pharma reported a net profit of 1.702 billion yuan, a year-on-year increase of 38.96% [1] - Kotec Power's net profit was 23.99 million yuan, increasing by 35.52% year-on-year [1] - Dongshan Precision reported a net profit of 758 million yuan, up 35.21% year-on-year [1] - Inspur Information achieved a net profit of 799 million yuan, a year-on-year increase of 34.87% [1] - Shenzhen Huaqiang reported a net profit of 236 million yuan, increasing by 33.45% year-on-year [1] - Conch Cement achieved a net profit of 4.368 billion yuan, up 31.34% year-on-year [1] - Jiuzhoutong reported a net profit of 1.446 billion yuan, increasing by 19.7% year-on-year [1] - Aofei Data achieved a net profit of 87.89 million yuan, a year-on-year increase of 16.09% [2] Decline and Loss - Huachang Chemical reported a net profit of 1.09 million yuan, a year-on-year decrease of 97.58% [2] - Meibang Apparel achieved a net profit of 993,030 yuan, down 87.07% year-on-year [2] - Toukeng Life reported a net profit of 275,930 yuan, a decrease of 58.41% year-on-year [2] - BlueFocus reported a net profit of 96.44 million yuan, down 47.33% year-on-year [2] - China Gold achieved a net profit of 31.9 million yuan, a decrease of 46.35% year-on-year [2] - Huaxi Biological reported a net profit of 22.1 million yuan, down 35.38% year-on-year [2] - Zhejiang New Energy achieved a net profit of 29.2 million yuan, down 34.65% year-on-year [2] - Hainan Mining reported a net profit of 28.1 million yuan, a decrease of 30.36% year-on-year [2] - Changying Precision achieved a net profit of 30.6 million yuan, down 29.37% year-on-year [2] - China Duty Free reported a net profit of 2.6 billion yuan, down 20.81% year-on-year [2] - Jiangling Motors achieved a net profit of 73.3 million yuan, down 18.17% year-on-year [2] - Donghua Software reported a net profit of 24.4 million yuan, down 15.78% year-on-year [2] - Hengda New Materials achieved a net profit of 3.4235 million yuan, down 12.68% year-on-year [2] - Yaoji Technology reported a net profit of 25.6 million yuan, down 9.98% year-on-year [2] - Ping An Insurance achieved a net profit of 68.047 billion yuan, down 8.8% year-on-year [2] - China Petroleum reported a net profit of 840.07 billion yuan, down 5.4% year-on-year [2] - 360 reported a net loss of 28.2 million yuan [2] - Electric Wind Power reported a net loss of 27.9 million yuan [2] Losses - Suzhou Keda reported a net loss of 21.7 million yuan [3] - Yuntian Lifa achieved a net loss of 20.6 million yuan [3] - Kosen Technology reported a net loss of 10.5 million yuan [3] - Xinyada reported a net loss of 5.2635 million yuan [3] - Chengfei Integration achieved a net loss of 1.49208 million yuan [3] - China Film reported a net loss of 11 million yuan, turning from profit to loss year-on-year [3]

三博脑科医院管理集团股份有限公司 董事会议事规则 第一章 总则 第一条 为了进一步规范三博脑科医院管理集团股份有限公司（以下简 称"公司"）董事会的议事方式和决策程序，促使董事会和董事落实股东会决 议，有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人 民共和国公司法》（以下简称"《公司法》"）《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板股 票上市规则》等法律法规、规范性文件及《三博脑科医院管理集团股份有限公 司章程》（以下简称"《公司章程》"）的相关规定，制定本规则。 第二条 本规则对公司全体董事、董事会秘书、高级管理人员和其他有 关人员都具有约束力。 第二章 董事 第三条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： (一) 无民事行为能力或者限制民事行为能力； (二) 因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩 序，被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓 刑的，自缓刑考验期满之日起未逾 2 年； (三) 担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企 业的破产负有个人 ...

三博脑科医院管理集团股份有限公司 股东会议事规则 第一章 总则 第一条 为规范三博脑科医院管理集团股份有限公司（以下简称"公司"） 的行为，保证股东会依法行使职权，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》和《公司章程》的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 本规则对公司及公司股东、董事、高级管理人员和列席股东会 会议的其他有关人员均具有约束力。 第四条 合法有效持有公司股份的股东均有权亲自出席或委托代理人 出席股东会，并依法享有各项股东权利。 第五条 股东（包括其委托代理人，下同）出席股东会应当遵守有关法 律、行政法规、规范性文件及《公司章程》的规定，自觉维护会议秩序，不 得侵犯其他股东的合法权益。 第六条 公司召开股东会时将聘请律师对以下问题出具法律意见并公 告： （一）会议的召集、召开程序是否符合法律、行政法规、《上市公司股东 会规则》和《公司章程》的规定； 1 / 19 第八条 股东会是公司的权力机构，依法行使下列职权： （一）选举和更换董事，决定有关董事的报 ...

三博脑科医院管理集团股份有限公司 章 程 2025 年 8 月 1 | | | 三博脑科医院管理集团股份有限公司 章程 第一章 总则 第一条 为维护三博脑科医院管理集团股份有限公司（以下简称"公司"）、 股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定由三博医院管理集团有限公 司整体变更设立的股份有限公司。公司在北京市海淀区市场监督管理局注册登记， 现持有统一信用代码为 91110108756735293H 的《营业执照》。 第三条 公司于 2023 年 3 月 10 日经中国证券监督管理委员会（以下简称"中 国证监会"）同意注册，首次向社会公众发行人民币普通股 39,612,900 股，于 2023 年 5 月 5 日在深圳证券交易所创业板上市。 第四条 公司注册名称：三博脑科医院管理集团股份有限公司 公司英文全称：Sanbo Hospital Management Group Limited 第五条 公司住所：北京市海淀区 ...

三博脑科医院管理集团股份有限公司 董事及高级管理人员离职管理制度 第一章 总则 第一条 为进一步完善三博脑科医院管理集团股份有限公司（以下简 称"公司"）董事、高级管理人员离职管理体系，促进公司健康、持续、稳 定发展，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司章程指引》等有关法律法规和规范性文件和《三博脑科医院管理集 团股份有限公司章程》（以下简称《公司章程》）的规定，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员 （总经理、副总经理、财务总监、董事会秘书）的辞职、任期届满、被解 除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事、高级管理人员可以在任期届满以前提出辞职。董 事、高级管理人员辞职应向公司提交书面辞职报告，公司收到辞职报告之 日起生效，公司将在两个交易日内披露有关情况。 除非法律法规、中国证监会和深圳证券交易所相关规则另有规定外， 出现下列规定情形的，在改选出的董事就任前，原董事仍应当依照法律、 行政法规、部门规章和《公司章程》的规定，履行职务，但存在相关法规 另有规定的除外： （一）董事任期届满未及时改选，或者董事在任期 ...